| |
|
|
|
CfPA - The Center for Professional Advancement, Orlando, FL
February 10-13, 2014
Who Should Attend
This broadly based course is intended for all scientists and technologists concerned with the development and processing of tablets, capsules and similar products, and with related drug regulatory affairs.
The material will be presented in such a way as to be of value to a varying level of expertise. This course will especially benefit those in:
• Quality Assurance
• Marketing
• Validation
• Purchasing
• R&D
• Regulatory Affairs
• Manufacturing/Production
• Engineering Support
Note: Persons seeking an in-depth treatment of only one or two of the major topics of this broadly based program may wish to consider alternative, more specialized courses offered by CfPA in this area of technology. Description
The main aim of this course is to review the science relating to tabletted and encapsulated pharmaceutical products. The course begins with a consideration of raw material testing and the basic aspects of powder and granulation technology, progresses through formulation of solid dosage forms to manufacturing processes and equipment including scale-up and technology transfer. The program concludes with key aspects of the evaluation of finished products and the regulatory constraints that must be considered at each stage. Formal sessions of the course are supplemented with informal discussion periods between lecturers and course participants and problem-solving sessions are held on both an open and private basis.
|
|
|
|
|
|
|
|
Organized by:
|
|
CfPA - The Center for Professional Advancement |
|
|
Invited Speakers:
|
|
Dr. Cecil W. Propst; Director R&D, SPI Pharma Group, Grand Haven
Dr. Cecil W. Propst is Director of R&D for SPI Pharma (Grand Haven site), a processor of a variety of specialty ingredients for the food, drug, cosmetic and related industries. He was Director of Quality Assurance and Technical Development at Fleming and Company and President of Manufacturing Chemists. His duties included system design, product and process development, and regulatory affairs. Previously, he served as cGMP Facilities Director for the University of Maryland at Baltimore in connection with the University’s contract with the FDA.
Dr. Propst also served as Director of Technical Development for Stellar Manufacturing, Director of Quality Compliance for SmithKline Beecham, Director of Quality Assurance for Norcliff Thayer (a Revlon Company), Group Leader/Product Development and Manager/Quality Control for Lewis Howe Company. He consults with TabTech for the chemical, diagnostic, food, engineering and beverage industries.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
n/a
|
|
|
|
|
|
|
|
Registration:
|
|
Please click here for registration information.
|
|
|
E-mail:
|
|
sberg@cfpa.com
|
|
|
|
|
|
|
|
|